CD274 and metastatic colorectal cancer: A recent study of cibisatamab, a bifunctional CD3+ T cell-CEA bispecific antibody able to introduce immunoreactive T-cells with CEA-expressing tumor cells, in combination with the anti-PD-L1 antibody atezolizumab reported promising (though early) disease control rate in patients with microsatellite stable metastatic colorectal cancer, [17] a population which does not respond commonly to antiPD-1/ anti-PD-L1 therapies [18].